|
1
|
Heldin CH: Development possible clinical
use of antagonists for PDGF and TGF-beta. Ups J Med Sci.
109:165–178. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee YM, Bae MH, Lee OH, et al: Synergistic
induction of in vivo angiogenesis by the combination of
insulin-like growth factor-II and epidermal growth factor. Oncol
Rep. 12:843–848. 2004.PubMed/NCBI
|
|
3
|
Cantón A, Burgos R, Hernández C, et al:
Hepatocyte growth factor in vitreous and serum from patients with
proliferative diabetic retinopathy. Br J Ophthalmol. 84:732–735.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Du S, Wang S, Wu Q, Hu J and Li T: Decorin
inhibits angiogenic potential of choroid-retinal endothelial cells
by downregulating hypoxia-induced Met, Rac1, HIF-1α and VEGF
expression in cocultured retinal pigment epithelial cells. Exp Eye
Res. 116:151–160. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Frank RN: Diabetic retinopathy. N Engl J
Med. 350:48–58. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ozaki H, Yu AY, Della N, et al: Hypoxia
inducible factor-1 alpha is increased in ischemic retina: Temporal
and spatial correlation with VEGF expression. Invest Ophthalmol Vis
Sci. 40:182–189. 1999.PubMed/NCBI
|
|
7
|
Willett CG, Boucher Y, di Tomaso E, et al:
Direct evidence that the VEGF-specific antibody bevacizumab has
antivascular effects in human rectal cancer. Nat Med. 10:145–147.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gragoudas ES, Adamis AP, Cunningham et Jr,
et al: Pegaptanib for neovascular age-related macular degeneration.
N Engl J Med. 351:2805–2816. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mongerard-Coulanges M, Migianu-Griffoni E,
Lecouvey M and Jolles B: Impact of alendronate and VEGF-antisense
combined treatment on highly VEGF-expressing A431 cells. Biochem
Pharmacol. 77:1580–1585. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shuey DJ, MeCallus DE and Giordano T:
RNAi: Gene-silencing in therapeutic intervention. Drug Discov
Today. 7:1040–1046. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Aravin AA, Klenov MS, Vagin VV, Rozovskiĭ
IaM and Gvozdev VA: Role of double-stranded RNA in eukaryotic gene
silencing. Mol Biol (Mosk). 36:240–251. 2002.(In Russian).
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stewart SA, Dykxhoorn DM, Palliser D,
Mizuno H, Yu EY, An DS, Sabatini DM, Chen IS, Hanh WC, Sharp PA, et
al: Lentivirus-delivered stable gene silencing by RNAi in primary
cells. RNA. 9:493–501. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Itakura J, Ishiwata T, Shen B, Kornmann M
and Korc M: Concomitant over-expression of vascular endothelial
growth factor and its receptors in pancreatic cancer. Int J Cancer.
85:27–34. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sharkey AM, Day K, Mcpherson A, Malik S,
Licence D, Smith SK and Charnock-Jones DS: Vascular endothelial
growth factor expression in human endometrium is regulated by
hypoxia. J Clin Endocrinol Metab. 85:402–409. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shweiki D, Itin A, Soffer D and Keshet E:
Vascular endothelial growth factor induced by hypoxia may mediate
hypoxia-initiated angiogenesis. Nature. 359:843–845. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Klagsburn M and D'Amore PA: Vascular
endothelial growth factor and its receptors. Cytokine Growth Factor
Rev. 7:259–270. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Elahy M, Baindur-Hudson S, Newsholme P and
Dass C: Mechanisms of PEDF mediated protection against ROS damage
in diabetic retinopathy and neuropathy. J Endocrinol.
222:R129–R139. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Aiello LP, Northrup JM, Keyt BA, Takagi H
and Iwamoto MA: Hypoxic regulation of vascular endothelial growth
factor in retinal cells. Arch Ophthalmol. 113:1538–1544. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Thieme H, Aiello LP, Takagi H, Ferrara N
and King GL: Comparative analysis of vascular endothelial growth
factor receptors on retinal and aortic vascular endothelial cells.
Diabetes. 44:98–103. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Song E, Zhu P, Lee SK, et al: Antibody
mediated in vivo delivery of small interfering RNAs via
cell-surface receptors. Nat Biotechnol. 23:709–717. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jia RB, Fan XQ, Wang XL, Zhang XQ, Zhang P
and Lu J: Inhibition of VEGF expression by plasmid-based RNA
interference in the retinoblastoma cells. Zhonghua Yan Ke Za Zhi.
43:493–498. 2007.(In Chinese). PubMed/NCBI
|
|
22
|
Wang J, Shi YQ, Yi J, et al: Suppression
of growth of pancreatic cancer cell and expression of vascular
endothelial growth factor by gene silencing with RNA interference.
J Dig Dis. 9:228–237. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shen J, Yang X, Xiao WH, Hackett SF, Sato
Y and Campochiaro PA: Vasohibin is up-regulated by VEGF in the
retina and suppresses VEGF receptor 2 and retinal
neovascularization. FASEB J. 20:723–725. 2006.PubMed/NCBI
|
|
24
|
Murata M, Takanmi T, Shimizu S, et al:
Inhibition of ocular angiogenesis by diced small interfering RNAs
(siRNAs) specific to vascular endothelial growth factor (VEGF).
Curr Eye Res. 31:171–180. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cai CM, Sun BC and Liu XY: Short hairpin
RNA targeting vascular endothelial growth factor effectively
inhibits expression of vascular endothelial growth factor in human
retinal pigment epithelium. Zhonghua Yan Ke Za Zhi. 42:334–337.
2006.(In Chinese). PubMed/NCBI
|
|
26
|
Xia XB, Xiong SQ, Song WT, Luo J, Wang YK
and Zhou RR: Inhibition of retinal neovascularization by siRNA
targeting VEGF (165). Mol Vis. 14:1965–1973. 2008.PubMed/NCBI
|
